Dr Dana Shor
Bhs MBBS MRCP FRCR
Languages spoken
English
Expert in
Lung cancer, Upper gastrointestinal cancers
Overview
Dr Dana Shor is a Consultant in Clinical Oncology who specialises in the treatment of lung and upper gastrointestinal (GI) cancers. She provides expert, compassionate care across a full range of treatments, including systemic therapies, conventional radiotherapy, and stereotactic ablative radiotherapy (SABR) for thoracic, upper GI malignancies and tumours of unknown primary.
Dr Shor completed a prestigious fellowship at the Odette Cancer Centre in Toronto, where she gained advanced expertise in SABR for lung, bone, and spine metastases, as well as stereotactic radiosurgery (SRS) for brain metastases.
In her current role at Cambridge University Hospital and Papworth Hospital, Dr Shor is part of a leading oncology team within the Department of Oncology. She serves as a principal investigator for several clinical trials, helping to advance future cancer care.
Dr Shor is committed to teaching and mentorship, having supported the British Oncology Network for Undergraduate Society. She is a trainee editor for the Clinical Oncology journal and contributes regularly to OncoFlash, providing updates on the latest radiotherapy research.
Education
- York university
- University of Toronto
- Member of the Royal College of Radiologists
- Member of the Medical Defence Union
Expertise and interests
- Systemic therapy and radiotherapy for lung cancer
- Systemic therapy and radiotherapy for upper GI cancer
- Systemic therapy and radiotherapy for CNS malignancies/benign conditions
- SRS for brain mets
- SABR for spine and bone mets
Awards
- NIHR Research Award (2017-2022)
Professional memberships
- Member of the Royal College of Radiologists
- Member of the Medical Defence Union
Publications
1. Shor D, Simoes R. OncoFlash - Research updates in a Flash! November 24 edition. Clin Oncol 36(11), 2024, 659-661
2. Shor D, Louie AV, Zeng KL, Menjak IB, Atenafu EG, Chia-Lin Tseng, Detsky J, Larouche J, Zhang B, Soliman H, Myrehaug S, Maralani P, Hwang DM, Sahgal A, Chen H. Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy. J Neurooncol. 2024 Mar 25. doi: 10.1007/s11060-024-04603-8. Epub ahead of print. PMID: 38526757.
3. Shor D, Khoo V, Jayaprakash KT, Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy, Clinical Oncology, March 2024. https://doi.org/10.1016/j.clon.2024.03.023.
4. Shor D, Simoes R. OncoFlash - Research updates in a Flash! January 24 edition. Clin Oncol (R Coll Radiol). 2024 Jan;36(1):3-5. doi: 10.1016/j.clon.2023.12.004. PMID: 38135360.
5. Shor D, Zeng L, Holden L , Chen H, Maralani P, Heyn C, Zhang B, Myrehaug SD, Tseng CL, Detsky J, Soliman H, Sahgal A. Staged Stereotactic radiosurgery as a novel adaptive approach to salvage previously irradiated brain metastases. International journal of radiation oncology biology physics, Volume 117, (2), Supplement, E150, October 1st 2023. https://doi.org/10.1016/j.ijrobp.2023.06.969
6. Shor D, Zeng LK, Chen H, Menjak I, Atenafu E, Tseng C.L, Detsky J, Larouche J, Zhang B, Soliman H, Maralani M, Myrehaug S, Louie, AV, Sahgal A. Biomarker status predicts for local control (lc) following spine stereotactic body radiotherapy (SBRT) in non-small cell lung cancer (NSCLC) patients with spinal metastases, Neurooncol Adv. 2023 Jul 12;5(Suppl 2):i4–5. doi: 10.1093/noajnl/vdad071.017. PMCID: PMC10337558. –i5, https://doi.org/10.1093/noajnl/vdad071.017
7. Slevin F, Pan S, Mistry H, Denholm M, Shor D, Oong Z, Price J, Jadon R, Fleming JC, Barnett G, Dixon L, Prestwich R, Thomson D. A Multicentre UK Study of Outcomes for Locally Advanced Sinonasal Squamous Cell Carcinoma Treated with Adjuvant or Definitive Intensity-modulated Radiotherapy. Clin Oncol (R Coll Radiol). 2021 Oct;33(10):e450-e46. doi: 10.1016/j.clon.2021.05.012. Epub 2021 Jun 17. PMID: 34147323
8. Shor D, Jadon R, Jephcott C, Wilson C. Chemoradiotherapy outcomes using intensity-modulated radiotherapy for anal squamous cell carcinoma – a single centre experience, Clinical Oncology, V32, Suppl1, Dec 1st 2020: E1,https://doi.org/10.1016/j.clon.2020.11.017.
9. Pan S, Slevin F, Shor D, Mistry P, Barnett G, Prestwich R, Dixon L, Thomson D, UK multicenter outcomes for treatment of sinonasal carcinomas, Clinical Oncology,V32, Suppl 1, 2020: E2. Dec 1st 2020. https://doi.org/10.1016/j.clon.2020.11.021
10. Shor D, Smith M, Abbas Z, Wade, R, Kapur G, Nobes J, Swannie H. The role of pelvic node irradiation in node positive prostate cancer; the Norfolk and Norwich University Hospital (NNUH) Experience 2011-2015. Clinical Oncology. V32. Issue 5. E134. May 1st 2020. https://doi.org/10.1016/j.clon.2020.01.022.
GMC registration
7151622
Dr Dana Shor reviews
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.